Mirtazapine and Methamphetamine Drug-drug Interaction Study
Key facts
- Who runs it
- San Francisco Department of Public Health
- Where
- Los Angeles and San Francisco, United StatesSee the 3 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 15 people enrolled
- Started
- 3 May 2021
- Ended
- 31 May 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Mirtazapine
- Methamphetamine
- Record updated
- 27 September 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- English-speaking
- age 18-55 years inclusive
- meet DSM-V criteria for MA use disorder, as diagnosed via SCID
- provide MA-positive urine during screening
- have a resting heart rate of 50-90
- have a systolic blood pressure ≤ of 100-150 mm Hg, and diastolic blood pressure of 45-90 Hg within two days prior to admission
- have a baseline EKG that demonstrates normal sinus rhythm, QTc < 440 msec in men or QTc < 450 msec in women
- have acceptable safety lab data, ALT / AST<3x upper limit nL; est GFR >50
- if female (except females of non-childbearing potential-e.g., at least 1 year post-menopausal or surgically sterile), not pregnant confirmed by negative pregnancy test nor lactating and willing to use a medically approved method of birth control to prevent pregnancy during the trial and for 7 days after the last dose of study medication
- For those who also use opioids and are on methadone maintenance treatment (Group 2), urine positive for methadone and negative for buprenorphine on admission
Who cannot take part
- current ongoing treatment with psychotropic medications (e.g. antidepressants, antipsychotics, antiepileptics, sedative/hypnotics, narcotic analgesics)
- urine positive for MA and other unplanned drugs on the day of admission and breathalyzer results negative for alcohol
- any prior adverse reaction to MA; including chest pain or epileptic seizure
- Have current cocaine, cannabis, or alcohol use disorder by DSM-V SCID
- current or past history of seizure disorder
- major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar illness but excepting stable major depressive disorder, generalized anxiety disorder, etc.) as assessed by the SCID
- have a current neurological disorder (e.g., organic brain disease, dementia) or medical condition which would make study compliance difficult or compromise informed consent
- history of suicide attempt(s) in the past 90 days or current suicidal intent or plan by SCID
- evidence of untreated or unstable serious medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease including active tuberculosis infection
- any serious medical or psychiatric AE after test infusion of MA 30mg IV (e.g. sustained SBP>200 or DBP>100; sustained pulse >(220-0.85xAge)
- seeking treatment for MA problems at the time of the study
- any other circumstances that, in the opinion of the investigators, would compromise participant safety and/or successful completion of the trial
Where in United States
- UCLA Medical CenterLos Angeles, United States
- San Francisco Department of Public HealthSan Francisco, United States
- Substance Use Research UnitSan Francisco, United States
About the trial
What the trial wants to find out
This is a drug-drug interaction (DDI) study of mirtazapine for methamphetamine (MA) use disorder (MUD) to ensure the safety of this medication in the presence of a relevant dose of MA for people actively-using MA.
Read full original descriptionShow less
Aim 1: To determine if mirtazapine alters the cardiovascular response to IV MA.
Aim 2: To determine if the pharmacokinetics of IV MA are altered by mirtazapine administration.
Aim 3: To evaluate the above aims in the setting of concomitant administration of methadone.
This study involves two simultaneous within-subject drug-drug interaction studies, each comprised of 12 participants. A total of 24 subjects will be enrolled who have methamphetamine use disorder who will be classified into 2 groups: (Group 1: no opioids; Group 2: opioid use disorder on methadone maintenance). Subjects will be randomized to the order of mirtazapine and placebo (i.e. one-half will receive mirtazapine first, then placebo; one-half will receive placebo first, then mirtazapine).
The 2 groups in the trial
- MirtazapineTreatment being tested
Mirtazapine 30 mg PO daily x 4 days
Treatment: Mirtazapine and Methamphetamine
- PlaceboPlacebo, for comparison
Placebo 30 mg PO Daily x 4 days
Treatment: Methamphetamine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1 Safety-interaction Study of Mirtazapine for the Treatment of Methamphetamine Use Disorder
- Record updated
- 27 September 2024